News AbbVie’s elagolix shows promise in uterine fibroids treatmen... AbbVie's elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for the pipeline drug, which could become a major earner for the company.
News UK court overturns AbbVie Humira patents Decision paves way for cheaper competitor in autumn 2018.
News Amgen's Humira biosimilar first to gain EU nod But patents could delay launch for more than a year.
News New Gilead and AbbVie hepatitis C combos filed in EU Companies aim to cut treatment time and side effects.
News J&J/AbbVie blood cancer drug gets fifth US indication Imbruvica approved in marginal zone lymphoma.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
